Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • LY364947: Selective TGF-β Receptor Kinase Inhibitor for C...

    2026-02-04

    LY364947: Selective TGF-β Receptor Kinase Inhibitor for Precision EMT and Fibrosis Research

    Principle and Setup: Mechanism of Action and Experimentation Rationale

    Transforming growth factor-β (TGF-β) signaling is pivotal in orchestrating cell fate decisions, fibrotic remodeling, and cancer metastasis through its type I receptor-mediated kinase activity. LY364947 is a potent and selective TGF-β type I receptor kinase inhibitor (IC50: 51 nM) that blocks kinase activity, thus abrogating downstream signaling events such as Smad2 phosphorylation. By disrupting this axis, LY364947 effectively inhibits epithelial-mesenchymal transition (EMT), a process central to tumor invasiveness and fibrotic disease progression, and modulates anti-fibrotic signaling in relevant preclinical models. Its selectivity and defined mode of action make it a gold-standard compound for dissecting TGF-β-dependent pathways, as evidenced by both cell-based and in vivo studies.

    APExBIO supplies LY364947 in multiple quantities, dissolved in DMSO to ensure maximum solubility (≥24.4 mg/mL), and recommends storage at -20°C for optimal stability. This compound is strictly for research use, providing scientists with a reliable tool to interrogate TGF-β signaling in a variety of disease models.

    Step-By-Step Workflow: Optimized Experimental Protocols with LY364947

    1. Compound Preparation and Handling

    • Obtain LY364947 from APExBIO, delivered in DMSO. If solid, dissolve to a stock concentration of 10–50 mM in 100% DMSO. Confirm complete dissolution by visual inspection or vortexing.
    • Aliquot stocks for single-use to minimize freeze-thaw cycles; store at -20°C. Prepare working solutions fresh for each experiment, diluting into culture medium with final DMSO ≤0.1% to avoid cytotoxicity.

    2. Cell-Based Assay Integration

    • Seed target cells (e.g., HOXB9-MCF10A, pancreatic, or retinal epithelial models) at consistent densities. Allow cells to adhere overnight.
    • Treat with LY364947 at 1–10 μM, based on published effective concentrations for robust inhibition of Smad2 phosphorylation and EMT marker modulation (see reference).
    • Include TGF-β1 stimulation controls to elicit pathway activation where appropriate.
    • Harvest cells at 24–72 hours for endpoint assays: Western blot (Smad2, E-cadherin, vimentin, fibronectin), qPCR (EMT genes), scratch-wound or transwell migration/invasion assays.

    3. In Vivo Workflow

    • For retinal degeneration models, administer LY364947 intravitreally or systemically at published doses (e.g., 5 mg/kg), as per established protocols (see example).
    • Monitor for attenuation of NMDA-induced retinal injury, vascular leakage, or fibrotic marker expression (immunohistochemistry, ELISA).

    These workflows are readily adaptable for anti-fibrotic research, preclinical TGF-β inhibitor screening, and signaling crosstalk studies.

    Advanced Applications and Comparative Advantages

    LY364947’s high selectivity for the TGF-β type I receptor kinase ensures precise pathway modulation with minimal off-target effects. Compared to pan-kinase or less selective inhibitors, LY364947 delivers consistent inhibition of Smad2 phosphorylation and more robust suppression of EMT phenotypes—in some studies, re-expressing E-cadherin and reducing vimentin/fibronectin levels by 50–80% in treated cell lines. This precision is especially valuable in delineating TGF-β’s role in migration, invasion, and fibrotic remodeling.

    In the context of tumor biology, recent mechanistic insight highlights the interplay between TGF-β/Smad and Wnt/β-catenin pathways. For example, the Gu et al. (2025) study demonstrated that dual targeting of CDK4/6 and BET proteins synergistically suppresses pancreatic tumor growth and reverses EMT by disrupting crosstalk between Wnt/β-catenin and TGF-β/Smad signaling. LY364947 is uniquely positioned to extend these findings by allowing researchers to parse TGF-β’s specific contribution in such combinatorial settings, particularly in models where EMT or fibrotic outcomes are confounded by parallel signaling axes.

    This compound’s utility is further underscored in anti-fibrotic research, as shown in this systems biology perspective, where LY364947 enables nuanced modulation of fibrosis-relevant gene networks. Moreover, its benchmark performance in reproducibility and sensitivity is highlighted in a comparative protocol guide, which demonstrates superior data reliability versus less-characterized competitors.

    Researchers aiming to model retinal degeneration or vascular damage will find LY364947 validated in rat NMDA-injury paradigms, where it significantly reduces tissue pathology and marker expression in vivo.

    Troubleshooting and Optimization Tips

    • Solubility Issues: LY364947 is insoluble in water and ethanol. Always dissolve in 100% DMSO for stock preparation. If precipitation occurs upon dilution, ensure gradual addition to pre-warmed culture medium and immediate mixing.
    • Loss of Activity: Avoid repeated freeze-thaw cycles of stock solutions. Use aliquots and store at -20°C. Prepare working dilutions immediately prior to use.
    • Variability in EMT Inhibition: Optimize dosing based on cell type and assay duration. Start with a 1–10 μM range; titrate as needed to achieve ≥70% inhibition of Smad2 phosphorylation, as assessed by Western blot or in-cell ELISA.
    • DMSO Toxicity: Maintain final DMSO concentration in culture below 0.1%. Include vehicle controls to monitor for off-target effects.
    • Interference with Combination Treatments: For experiments involving pathway crosstalk (e.g., Wnt/β-catenin, as in Gu et al.), stagger treatments or use sequential dosing to avoid masking synergistic effects.

    For additional strategies, the mechanistic insight article expands on integrating LY364947 in translational workflows, especially in complex disease models.

    Future Outlook: Unlocking Next-Generation TGF-β Signaling Modulation

    LY364947’s track record in pathway-specific inhibition, EMT reversal, and anti-fibrotic research positions it at the forefront of preclinical TGF-β inhibitor development. As mechanistic studies (e.g., those dissecting Wnt/β-catenin and TGF-β/Smad crosstalk) proliferate, LY364947 will remain indispensable for unraveling these axes in cancer, fibrosis, and degenerative disease models. Its compatibility with combination screens, advanced omics, and in vivo functional readouts ensures continued relevance for both academic and translational pipelines.

    Looking ahead, integration of LY364947 into high-content phenotypic screens and single-cell analyses may yield new insights into the temporal dynamics of EMT inhibition and anti-fibrotic response. The expanding toolbox for selective TGF-β receptor kinase inhibitor research, anchored by APExBIO’s commitment to quality and reproducibility, promises to accelerate discovery from bench to bedside.